Insulin Syringe Assembly Machine

And other Insulin Syringe Assembly Machine may choose a part of imitation, part of the path of innovation. It is reported that the types of drugs involved in the bulk purchase remain unchanged, but the purchase price shall not be higher than the previous bid price of the '4+7' pilot quantity purchase.　　 At present, under the background of the nationwide expansion of mass procurement, my country's centralized drug procurement has entered a new stage. Companies with production technology and production management advantages, but no genes, can develop into OEM companies.　

However, while implementing volume purchases, the industry suggests that supporting measures are needed to ensure that the decline in pharmaceuticals does not affect corporate profits. In the long run, it will benefit large companies with strong capabilities or leading companies in the pharmaceutical sector. Valuable innovative drugs and excellent generic drugs Will be more competitive. With the advancement of volume procurement, it is expected to further achieve the effect of squeezing out drug marketing costs 'moisture' and reducing drug prices.　　

At the same time, he said that after purchasing in quantity, generic drug companies may face further division of labor. The concentration of the industry has continued to increase, and the survival of the fittest is obvious. This also means that ;4+7; volume purchases will be extended to the whole country. '4+7' Among the impacts brought by volume purchases, one very significant point is the decline in drug prices.　　Industry analysts said that mass procurement will undoubtedly accelerate the reshuffle of the generic drug industry, and cost control, quality, and price reduction will be the focus of the next development. It can be seen that volume procurement will be a development opportunity for many large companies.　　In the pharmaceutical industry, excessive sales expenses and insufficient investment are common problems in the industry, which seriously affect the performance and financial status of pharmaceutical companies.　　

At the 2019 Beijing Municipality's Investor Group Reception Day for Listed Companies, Osaikang Financial Director Han Tao also pointed out that the national mass procurement policy is conducive to the expansion and strengthening of leading companies in the pharmaceutical segment.　　

Megosztás a facebookon